Genetic Signatures UK

Genetic Signatures is a global molecular diagnostics company specialising in medium- to high-throughput syndromic testing for infectious diseases. Our automated solutions help laboratories improve efficiency, reduce costs, and support faster, more informed patient management.
Our syndromic panels play a vital role in infection prevention, control, and disease surveillance. The EasyScreen™ Pan-Enteric assay detects 24 clinically relevant viral, bacterial, and parasitic pathogens in a single streamlined workflow, reducing hands-on time and operational burden.
All assays are powered by our proprietary 3base® technology, enabling highly efficient multiplex PCR through simplified pathogen detection.

Approach to Healthcare

Syndromic PCR testing has revolutionised diagnostic pathways for urgent and at need critical patients, however this has always come at a cost restricting laboratories and clinical decision makers to a Triage method which often results in a process that ends as soon as the first pathogen is detected, Genetic signatures believe that every decision maker deserves to see the full picture to make informed decisions in a single instance.

Impact of Product/Services on Healthcare

Seeing the full picture for multiple patients in a single instance allows the Infection and Prevention Control team to make timely informed decisions for both individual patients and wards, improving patient outcomes and reducing potential ward closures.
Whilst guidelines have recommended the testing of all in-patients for Norovirus, our panel goes beyond this, testing 7 viral targets providing additional confidence for immunocompromised In-patients.

Innovation

All Genetic Signatures’ diagnostic assays are underpinned by our proprietary 3base® technology which reduces the genetic complexity of target pathogen sequences detected within our workflow, delivering a number of benefits:
•Simplified uniformed samples processing of Viral, Bacterial and Parasitic pathogens.
•Simplified and harmonised PCR conditions allowing one process for Viral, Bacterial and Parasitic pathogens.
•Assay is less susceptible to viral mutation (Less need to redesign assay).
•Reduced risk of PCR environmental contamination within the workflow (Improved lab uptime).

Future Direction